Oxford BioDynamics Plc (LON:OBD) CEO Christian Hoyer Millar talks to DirectorsTalk about with its co-operation agreement with GL Capital Group to address the growing demand for healthcare and personalised medicine in China. Christian explains why China and the potential, provides some detail around the personalised medicine market in China, why GL Capital, first refusal and the next steps for OBD and GL.
Oxford BioDynamics Plc is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.
The Company’s award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.